Triazole derivatives useful as Axl inhibitors

A method of treating a disease or condition associated with Axl catalytic activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (Ia) or formula (Ib):

• wherein, independently at each occurrence:
• A is —C(O)— or —C(S)—;
• R1 is aryl substituted with at least one of —R8—OR10 or —R8—O—R9—CN, where each R8 is a direct bond and R10 is selected from the group consisting of optionally substituted heterocyclylalkyl, optionally substituted heteroarylalkyl and optionally substituted aralkyl, and optionally substituted with one or more substituents selected from the group consisting of halo, haloalkyl, alkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and alkoxy;
• R2, R4 and R5 are each independently hydrogen, alkyl, aryl, aralkyl, —C(O)R10 or —C(O)N(R6)R7;
• R3 is one of the following:
• a) aryl optionally substituted with one or more substituents selected from the group consisting of alkyl, halo;
• haloalkyl, nitro, cycloalkyl, cycloalkylalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted heterocyclyl, —R8—OR10, —R8—C(O)OR10, —R8—OC(O)R10, —R8—O—R9—C(O)OR10, —R8—O—R9—C(O)N(R6)R7, —S(O)pR6 (where p is 0, 1 or 2), —S(O)tN(R6)R7 (where t is 1 or 2), —R8—N(R6)R7, —R8—N(R6)C(O)R10, —R8—N(R6)C(O)OR10 and —R8—CN;
• or
• b) optionally substituted heteroaryl;
• R6 and R7 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, —R9—CN, —R9—NO2, —R9—N(R10)2, —R9—C(O)OR10 and —R9—C(O)N(R10)2;
• optionally, R6 and R7, together with the nitrogen to which they are attached, form an optionally substituted N-heteroaryl or an optionally substituted N-heterocyclyl;
• each R8 present in a R3 substituent is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;
• each R9 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain;
• and
• R10 present in the R2, R4 and R5 substituents and each R10 present in a R3 substituent, a R6 substituent or a R7 substituent is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, and optionally substituted heteroarylalkynyl;
• as an isolated stereoisomer or tautomer thereof or mixtures thereof,
• or a pharmaceutically acceptable salt or N-oxide thereof.